DURECT Corporation (DRRX)
DRRX Stock Price Chart
Explore DURECT Corporation interactive price chart. Choose custom timeframes to analyze DRRX price movements and trends.
DRRX Company Profile
Discover essential business fundamentals and corporate details for DURECT Corporation (DRRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
28 Sept 2000
Employees
21.00
Website
https://www.durect.comCEO
James E. Brown D.V.M.
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
DRRX Financial Timeline
Browse a chronological timeline of DURECT Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.18, while revenue estimate is $300.00K.
Earnings released on 12 Aug 2025
EPS came in at -$0.07 surpassing the estimated -$0.13 by +46.15%, while revenue for the quarter reached $447.00K , beating expectations by +49.00%.
Earnings released on 13 May 2025
EPS came in at -$0.13 matching the estimated -$0.13, while revenue for the quarter reached $321.00K , beating expectations by +10.06%.
Earnings released on 26 Mar 2025
EPS came in at -$0.06 falling short of the estimated $0.06 by -200.00%, while revenue for the quarter reached -$3.89M , missing expectations by -156.38%.
Earnings released on 13 Nov 2024
EPS came in at -$0.14 surpassing the estimated -$0.17 by +17.65%, while revenue for the quarter reached $1.93M , missing expectations by -72.10%.
Earnings released on 13 Aug 2024
EPS came in at -$0.12 surpassing the estimated -$0.17 by +29.41%, while revenue for the quarter reached $2.17M , missing expectations by -12.81%.
Earnings released on 13 May 2024
EPS came in at -$0.25 falling short of the estimated -$0.21 by -19.05%, while revenue for the quarter reached $1.83M , missing expectations by -32.83%.
Earnings released on 27 Mar 2024
EPS came in at -$0.27 surpassing the estimated -$0.36 by +25.00%, while revenue for the quarter reached $2.67M , beating expectations by +7.62%.
Earnings released on 13 Nov 2023
EPS came in at -$0.40 surpassing the estimated -$0.41 by +2.44%, while revenue for the quarter reached $1.74M , missing expectations by -29.68%.
Earnings released on 9 Aug 2023
EPS came in at -$0.46 falling short of the estimated -$0.45 by -2.22%, while revenue for the quarter reached $2.08M , missing expectations by -29.22%.
Earnings released on 8 May 2023
EPS came in at -$0.52 falling short of the estimated -$0.50 by -4.00%, while revenue for the quarter reached $2.05M , missing expectations by -28.93%.
Earnings released on 7 Mar 2023
EPS came in at -$0.46 surpassing the estimated -$0.53 by +13.21%, while revenue for the quarter reached $3.32M , missing expectations by -4.63%.
Stock split effective on 6 Dec 2022
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 2 Nov 2022
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $11.98M , missing expectations by -7.78%.
Earnings released on 4 Aug 2022
EPS came in at -$0.50 falling short of the estimated -$0.40 by -25.00%, while revenue for the quarter reached $2.08M , missing expectations by -45.98%.
Earnings released on 4 May 2022
EPS came in at -$0.50 matching the estimated -$0.50, while revenue for the quarter reached $1.92M , missing expectations by -16.13%.
Earnings released on 7 Mar 2022
EPS came in at -$0.30 surpassing the estimated -$0.50 by +40.00%, while revenue for the quarter reached $7.30M , beating expectations by +247.48%.
Earnings released on 2 Nov 2021
EPS came in at -$0.40 matching the estimated -$0.40, while revenue for the quarter reached $2.17M , beating expectations by +11.03%.
Earnings released on 29 Jul 2021
EPS came in at -$0.40 matching the estimated -$0.40, while revenue for the quarter reached $2.30M , missing expectations by -36.90%.
Earnings released on 4 May 2021
EPS came in at -$0.50 matching the estimated -$0.50, while revenue for the quarter reached $2.21M , beating expectations by +33.33%.
Earnings released on 4 Mar 2021
EPS came in at -$0.40 falling short of the estimated -$0.30 by -33.33%, while revenue for the quarter reached $2.21M .
Earnings released on 2 Nov 2020
EPS came in at -$0.50 falling short of the estimated -$0.40 by -25.00%, while revenue for the quarter reached $2.68M , beating expectations by +25.00%.
DRRX Stock Performance
Access detailed DRRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.